ACCESSWIRE
02 Aug 2022, 00:37 GMT+10
GOTHENBURG, SE / ACCESSWIRE / August 01, 2022 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB (Nasdaq Stockholm:IRLAB A) today announced that the number of votes and shares in IRLAB Therapeutics AB have changed as a result of the share issue that was concluded in April 2022.
The increased number of shares was registered by the Swedish Companies Registration Office during July 2022. As a result of the share issue, the number of votes and outstanding Class A shares has increased by 120,000 from 51,668,630 to 51,788,630. The number of Class B shares has not changed and is 79,776. The total number of shares and votes after the change amounts to 51,868,406. The share capital has increased by SEK 2,400 from SEK 1,034,968.12 to SEK 1,037,368.12,
More information about the share issue is found in the press release from April 22: IRLAB acquires know-how connected to the P003 project aimed at an innovative treatment for Parkinson's disease.
For more information
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se
This information is information that IRLAB Therapeutics is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2022-08-01 16:10 CEST.
About IRLAB
IRLAB discovers and develops novel treatments of Parkinson's disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult complications related to Parkinson's disease. In 2021, IRLAB entered an exclusive global license agreement with Ipsen for the development and commercialization of mesdopetam.
Through the systems biology based Integrative Screening Process (ISP), its IRLABs proprietary research platform, IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders. In addition to IRLAB's strong clinical pipeline, IRLAB runs several preclinical programs with IRL942 and IRL757 currently in development towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.
Attachments
Changed number of shares and votes in IRLAB Therapeutics AB
SOURCE: IRLAB Therapeutics
Get a daily dose of Kansas City Post news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Kansas City Post.
More InformationWASHINGTON D.C.: Despite the U.S. Food and Drug Administration's 2016 crack downon fruity, sweet-flavored e-cigarettes that can cause teens to ...
LONDON, England: Official figures have been released indicating that in the year to June, the UK recorded its highest increase ...
WASHINGTON D.C.: The U.S. Food and Drug Administration has approved the sale of over-the-counter hearing aids for people with mild ...
DHAKA, Bangladesh - Michelle Bachelet has urged the Bangladesh government to establish an independent investigation into allegations of enforced disappearances. ...
LONDON, England: Despite a legal challenge in London's High Court in early September, the UK government is continuing to pursue ...
NEW DELHI, India: During his national day address this week, Prime Minister NarendraModi said India will seek to become a ...
NEW YORK, New York - U.S. stocks retreated sharply on Friday as sellers swarmed Wall Street. The upward trend in ...
NEW YORK CITY, New York: Months after the U.S. faced acute shortages of baby formula, this week two major U.S. ...
SYDNEY, NSW, Australia - Stocks were in the doldrums in Asia on Friday as investors weighed up potential Federal Reserve ...
LONDON, England: As surging food costs are further squeezing household budgets, inJuly consumer price inflation in the UK jumped to ...
NEW DELHI, India: After a decline in prices reaching a 2-year low encouraged investors to purchase silver in 2022, India's ...
NEW YORK CITY, New York: The American hedge fund Third Point has purchased a stake worth some $1 billion in ...